A review and expert opinion of the use of certolizumab for Crohn's disease

Bibliography

• Loftus CG, Loftus EV Jr, Harmsen WS, Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940 – 2000. Inflamm Bowel Dis 2007;13:254-61
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A, Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, Predictors of Crohn's disease. Gastroenterology 2006;130:650-6
   PubMed Web of Science ®Google Scholar
• Mekhjian HS, Switz DM, Melnyk CS, Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77:898-906
   PubMed Web of Science ®Google Scholar
• Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther 2009;29:605-14
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91
   PubMed Web of Science ®Google Scholar
• Scherl E, Bosny P-L, Lee S. Formation of autoantibodies in patients with moderate to severe Crohn's disease, receiving continuous and interrupted CZP therapy with or without concomitant immunosuppressants. In American College of Gastroenterology 2011 abstracts; Washington DC
   Google Scholar
• Brynskov J, Foegh P, Pedersen G, Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Hanauer SB, Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702; e1
   PubMed Web of Science ®Google Scholar
• Schreiber S, Lawrance IC, Thomsen OØ, Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease – subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185-93
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8; quiz e10–11
   PubMed Web of Science ®Google Scholar
• Colombel JF, Lemann M, Bouhnik Y, Endoscopic mucosal improvement in patients with active crohn's disease. treated with certolizumab pegol: week 10 and 54 results of the music trial [abstract]. Gastroenterology 2010;138(5 Suppl 1):S-166
   Google Scholar
• Sandborn WJ, Abreu MT, D'Haens G, Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95 e2.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen OØ, Schreiber S, Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9
   PubMed Web of Science ®Google Scholar
• Lacroix BD, Parker GL. Dosing with certolizumab pegol (CZP) 200 mg every 2 weeks (Q2w) provides higher plasma trough concentrations than 400 mg every 4 weeks (Q4w). Gastroenterology 2010;138(Supp 1):S163-4
   Google Scholar
• Lee SD, Ko C, Wahbeh G, Assessment of the Efficacy of Certolizumab Pegol for the Treatment of Crohn's Disease at a Single North American Center, in American College of Gastroenterology2010: San Antonio, TX. Available from: http://www.uwgi.org/news/acg2010_P1132.pdf [Last acccessed 17 January 2012]
   Google Scholar
• Feagan BG, Reilly MC, Gerlier L, Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
   PubMed Web of Science ®Google Scholar
• Certolizumab Pegol. 10/2011; 9/2011. Brussels, Belgium: UCB 2011. Available from: http://www.cimzia.com/pdf/Prescribing_Information.pdf [Last accessed 17 January 2012]
   Google Scholar
• Mahadevan U, Sandborn WJ, Li DK, Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133:1106-12
   PubMed Web of Science ®Google Scholar
• Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14:1736-50
   PubMed Web of Science ®Google Scholar
• Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood. Arthritis Rheum 2010;62(Suppl 10):718
   Google Scholar
• Porter C, Kopotsha T, Smith BJ, No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro (abstract). Ann Rheum Dis 2010;69(Suppl 3):210
   PubMedGoogle Scholar
• Garty BZ, Ludomirsky A, Danon YL, Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994;1:667-9
   PubMedGoogle Scholar
• Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero., in Digestive Disease Week (DDW)2011: Chicago, IL. Avaialable from: http://www.ddw.org/user-assets/documents/PDF/05_press/11/DDW%202011%20Drugs%20Abstracts.pdf [Last accessed 17 January 2012]
   Google Scholar
• Hanauer SB, Panes J, Colombel JF, Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Schoepfer AM, Bansky G, Efficacy and safety of certolizumab pegol in an unselected Crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2011;17:1530-9
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Vavricka SR, Binek J, Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Inflamm Bowel Dis 2010;16:933-8
   PubMed Web of Science ®Google Scholar